Review {#Sec1}
======

Giant cell tumor of bone (GCTB) is a primary intramedullary tumor which is supposedly benign but can be locally aggressive and even metastatic \[[@CR1]--[@CR3]\]. Its name originated from the giant cells found within the tumor. Those giant cells share specific markers with osteoclasts such as tartrate-resistant acid phosphatase \[[@CR4]\], cathepsin K \[[@CR5]\], carbonic anhydrase II \[[@CR6]\], calcitonin receptor \[[@CR7]\] and receptor activator of nuclear factor-κB (RANK) \[[@CR8]\]. They both have bone resorption capabilities, but giant cells are significantly larger than the osteoclasts and have hundreds of nuclei \[[@CR9]\].

GCTB account for 5% of primary skeletal tumors and 21% of all benign bone tumors \[[@CR10], [@CR11]\]. It has the highest prevalence among the population aged between 20 and 40-years-old and has a slight female predominance \[[@CR12]\], with the female to male ratio of 1.3 to 1.5:1.0 \[[@CR13]\]. The most usual sites for GCT include distal femur, proximal tibia and distal radius \[[@CR14]--[@CR18]\]. The incidence of GCTs in small bones is less than 1% of all GCT cases \[[@CR19], [@CR20]\].

Diagnosis of giant cell tumor of bone {#Sec2}
=====================================

Conventional diagnostic methods of GCTB include its clinical, radiological and histopathological manifestations. Diagnostically, typical clinical manifestations of GCTB include regional pain, swelling and occasionally history of pathological fracture \[[@CR21]\]. Radiographs demonstrate an eccentric lytic lesion with cortical extension. Histologically, GCT consists of multiple multinucleated giant cells with strong phenotypic similarities to osteoclasts and spindle-shaped proliferative stromal cells \[[@CR15], [@CR22]\].

More recently, the increasingly popular application of novel imaging techniques such as positron emission tomography/computerized tomography (PET/CT) has made the diagnosis of primary and metastatic GCTB more accurate \[[@CR23]\]. Furthermore, basic research has also provided diagnostic gene markers such as P53, P63 and P73 \[[@CR24], [@CR25]\], as well as KTN 1, NEB, ROCK1 and ZAK \[[@CR26]\]. However, more research is needed before these biomarkers can be used in clinical practice.

Pulmonary metastasis of giant cell tumor of bone {#Sec3}
================================================

Prevalence {#Sec4}
----------

Although rare, GCTB can be multicentric or arise in locations where it is difficult to be surgically removed. The course of progression of GCTB varies and can range from local bony destruction to local metastasis. The distant metastasis and malignant transformation are extremely rare conditions \[[@CR27]\]. Rare cases of metastases to other sites have been described in the literature. Those reported include the lung, lymph nodes \[[@CR28]\], liver, soft tissue \[[@CR29]\], brain, mediastinum, scalp, kidney and penis.

Based on the current literature, approximately 3% of GCTB metastasizes to the lung (Table [1](#Tab1){ref-type="table"}). Pulmonary metastasis is very rarely discovered during diagnosis of the initial GCTB, but more frequently in cases of recurrence. The interval from the time of surgery on the primary lesion to the occurrence of pulmonary metastasis can be as little as several months or more than 10 years. However, in most cases metastases were found within three years after the surgical treatment of the initial lesion \[[@CR30], [@CR31]\]. Based on the current literature (Table [1](#Tab1){ref-type="table"}), approximately 3% of GCTB metastasizes to lung at certain time points after the confirmed diagnosis of primary GCTB.Table 1**Some studies on pulmonary metastasis of giant cell tumors of bone**Study (Author/year)Time of follow upNumber of patientsRatio of pulmonary metastasisErrani *et al*. 2010 \[[@CR32]\]91 (36-204) months3494%Kremen *et al*. 2012 \[[@CR33]\]0.1-312 months2302%Takeuchi *et al*. 2011 \[[@CR34]\]2-180 months1107.5%Klenke *et al*. 2011 \[[@CR35]\]108 (36-233)months1184.2%Viswanathan *et al*. 2010 \[[@CR36]\]4 months-12 years4701.7Balke *et al*. 2008 \[[@CR37]\]60 (8-280) months2143.3%Donthineni *et al*. 2006 \[[@CR38]\]18-126months5113.7%Faisham *et al*. 2006 \[[@CR39]\]12-60 months2030%Dominkus *et al*. 2006 \[[@CR30]\]3 months to 11.9 years6492.1%Prosser *et al*. 2005 \[[@CR40]\]70 (24-214) months1371.6%Su *et al*. 2004 \[[@CR41]\]62 (28-138) months871.2%Trieb *et al*. 2001 \[[@CR42]\]11 (4-43) years470%Blackley *et al*. 1999 \[[@CR43]\]80 (29-132) months591.7%O'Donnell *et al*. 1994 \[[@CR44]\]4 (2-10) years600%Kay *et al*. 1994 \[[@CR45]\]23-120 months669.1%Campanacci 1 *et al*. 987 \[[@CR1]\]2-44 years2802.1%McDonald *et al*. 1986 \[[@CR46]\]84 (min 24) months1463.2%

Factors related to the pulmonary metastasis of giant cell tumor of bone {#Sec5}
-----------------------------------------------------------------------

There is no consensus on which factors may affect the likelihood of pulmonary metastasis of GCTB. However, several independent studies on some special types of GCTB may bring some insights into this issue. For example, Faisham *et al*. \[[@CR39]\] have reported a pulmonary metastasis ratio of 30% in patients with grade 3 GCTB by Campanacci's classification, indicating that the tumor grading might be an important prognostic factor for the prediction of pulmonary metastasis of GCTB. Donthineni *et al*. \[[@CR38]\] have reported a pulmonary metastasis ratio of 13.7% in patients with GCTB which occur primarily on spine, and Errani *et al*. \[[@CR32]\] reported a higher incidence of pulmonary metastasis of GCTB located in proximal femur and distal radius, indicating that the location of primary lesion might also be a prognostic factor. However, most authors believe that there is no significant relationship between the location of GCTB and its risk of pulmonary metastasis.

Rock *et al*. \[[@CR47]\] had reported a six-fold higher risk of lung metastasis in patients who experienced local recurrence of GCTB compared with patients with no history of local recurrence. Studies by Rock and several other authors indicate that higher risk patients with recurrent GCTB should be carefully monitored for pulmonary metastases after the appropriate treatment of the recurrent lesion (Table [2](#Tab2){ref-type="table"}). Most studies assume that local recurrence of GCTB is a risk factor for lung metastasis.Table 2**Studies involving the relationship between local recurrence and pulmonary metastasis of GCTB**Study (Author/year)Number of patientsNumber of patients with pulmonary metastasisLocal recurrenceKremen *et al*. 2012 \[[@CR33]\]230528Klenke *et al*. 2011 \[[@CR35]\]118524Errani *et al*. 2010 \[[@CR32]\]3491452Prosser *et al*. 2005 \[[@CR40]\]1372226Trieb *et al*. 2001 \[[@CR42]\]47011Blackley *et al*. 1999 \[[@CR43]\]591012Kay *et al*. 1994 \[[@CR45]\]66618O'Donnell *et al*. 1994 \[[@CR44]\]60015Viswanathan *et al*. 2010 \[[@CR36]\]470813 of 24 patients with lung metastasisTubb *et al*. 1992 \[[@CR48]\]7 of 13 patients with lung metastasisGoldenberg *et al*. 1970 \[[@CR28]\]21865 of 6 patients with lung metastasis

Moreover, literature of basic research has also provided us with methods to predict the possibility of pulmonary metastasis. For example, pro-osteoclastogenic cytokines such as receptor activator of nuclear factor kappa-B ligand (RANKL), interleukin (IL)-6 and tumor necrosis factor (TNF), as well as monocyte-recruiting chemokines such as stromal cell-derived factor-1 (SDF-1) and monocyte chemoattractant protein (MCP)-1, participate in unfavorable osteoclastogenesis and bone destruction \[[@CR49]\]. High expression of those cytokines and chemokines may help predicting the metastatic potential and prognosis of GCTB.

Treatment {#Sec6}
---------

Treatment of giant cell tumor of bone is still one of the most controversial and discussed issues \[[@CR50]\]. The course of progression of metastatic pulmonary disease has been found to be as unpredictable as the primary tumor \[[@CR51]\]. Since the incidence of pulmonary metastasis of GCTB is rather rare, there is no study on the systematic treatment of metastatic GCTB in the current literature. However, since the recurrence rate of GCTB is significantly related to its pulmonary metastasis, studies concerning treatment methods and the recurrence rate of GCTB may provide guidance for the prevention of metastasis and achieve a better prognosis.

Surgical treatment {#Sec7}
------------------

Surgical treatment options for primary GCTB lesions include intralesional surgery and wide resection. Intralesional surgery has a higher recurrence rate but does preserve adjacent joint function. On the other hand, although wide resection may prevent metastasis, it may seriously impair the function of adjacent joints. When curettage is performed, local adjuvants such as polymethylmethacrylate (PMMA), phenol, alcohol, cryotherapy and hydrogen peroxide have been reported to significantly decrease the rate of local recurrence and pulmonary metastasis \[[@CR10], [@CR11], [@CR38], [@CR52], [@CR53]\]. However, some other studies \[[@CR40], [@CR54]\] failed to find any positive therapeutic effect of these adjacent measures. In a Scandinavian Sarcoma Group multicentric study by Kivioja *et al*. \[[@CR11]\] involving 294 patients, the recurrence rate of GCTB was 20% in patients treated with bone cement, which is significantly lower (*P* = 0.001) than the 56% recurrence rate in patients who underwent intralesional surgery with bone grafts. On the contrary, in a Canadian multicentric study of 186 patients by Turcotte *et al*. \[[@CR55]\], filling the remnant cavity with bone cement did not significantly reduce the recurrence rate of GCTB (Table [3](#Tab3){ref-type="table"}).Table 3**Recurrence rates after different surgical treatment of giant cell tumors of bone**Study (Author/year)Number of patientsWide resectionIntralesional curettageIntralesional curettage + regional burringIntralesional curettage + PMMAKlenke *et al*. 2011 \[[@CR35]\]1185N/A32+ phenol + burrin:15Errani *et al*. 2010 \[[@CR32]\]34912N/A18Balke *et al*. 2008 \[[@CR37]\]214014047+phenol: 38Kivioja *et al*. 2008 \[[@CR11]\]2941251N/A22Knochentumoren 2008 \[[@CR52]\]256249N/A+phenol:69Malek *et al*. 2006 \[[@CR56]\]40N/AN/A33N/AMcGough *et al*. 2005 \[[@CR57]\]183N/A46N/AN/AProsser *et al*. 2005 \[[@CR40]\]1370N/AN/A+burring: 21Su *et al*. 2004 \[[@CR41]\]873N/AN/A+phenol: 18Turcotte *et al*. 2002 \[[@CR55]\]18634N/AN/A+phenol + burring:55Blackley *et al*. 1999 \[[@CR43]\]59N/AN/A12N/ACampanacci *et al*. 1987 \[[@CR1]\]280027N/A8McDonald 1986 \[[@CR45]\]1467N/A34N/AResults from the current literature implies that the recurrence ratio of GCT is: Intralesional curettage \> Intralesional curettage + regional burring \> Intralesional curettage + local adjuvants + PMMA \> Wide resection.

Moreover, Enneking's and Campanacci's classifications \[[@CR2], [@CR58]\] are helpful tools for planning the initial surgical treatment. For instance, stage III GCTB is best managed with wide resection for better local control. Faisham *et al*. \[[@CR39]\] proposed that aggressive treatment of pulmonary metastasis is mandatory in the management of aggressive GCTB. Surgical excision of solitary and surgically-accessible lesions as well as lung metastases is now widely accepted as the treatment of choice, with an acceptable long-term survival rate \[[@CR45]\].

Drug treatment {#Sec8}
--------------

The anti-osteoclastic effects of bisphosphonates, along with their ability to protect bone from further resorption, make bisphosphonates potential candidates for the treatment of GCTB, and studies have confirmed their efficacy \[[@CR59]\]. Balke *et al*. \[[@CR37]\] examined clinical and radiological outcomes of treatment with amino bisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centers. Most inoperable sacral or pelvic tumors did not increase in size and no further recurrence or metastasis was observed in patients with recurrent GCTB. Lung metastases did not increase in size or number following treatment, suggesting that bisphosphonates may be useful against the progression of metastatic GCTB lesion in lung.

Denosumab, a fully human monoclonal antibody that specifically inhibits normal and tumor-associated bone lysis by preventing RANKL-mediated formation and activation of multinucleated osteoclasts or giant cells from RANK-positive mono-nuclear preosteoclasts and macrophages \[[@CR21]\], has been proved to be able to reduce the number of RANK-positive giant cells and proliferative stromal cells \[[@CR15]\]. In the study of Thomas *et al*. \[[@CR60]\], 30 out of 35 (86%; 95% CI 70 to 95) of evaluable patients had a positive tumor response after the treatment of denosumab. It is likely a novel and effective method with great potential in the treatment of GCTB \[[@CR61]\].

Prognosis {#Sec9}
---------

For lung metastasis, appropriate surgical resection such as metastasectomy, wedge resection or lobectomy should be carried out if it is possible to prevent progressive pulmonary dysfunction \[[@CR30], [@CR62]\]. Because pulmonary metastases are rare and timely surgical and chemotherapeutic treatment is usually successful (Table [4](#Tab4){ref-type="table"}, see Figures [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"} for an example case), we believe the potential for metastases should not by itself be an indication for wide resection of primary tumors.Table 4**Number of patients with the incidence of pulmonary metastasis of giant cell tumors of bone**Study (Author/year)Number of patientsCases with pulmonary metastasisSurvivors at the last follow upKremen *et al*. 2012 \[[@CR33]\]23054Takeuchi *et al*. 2011 \[[@CR34]\]11088Errani *et al*. 2010 \[[@CR32]\]3491410\*Klenke *et al*. 2011 \[[@CR35]\]11854Viswanathan *et al*. 2010 \[[@CR36]\]47088Faisham *et al*. 2006 \[[@CR39]\]2065Dominkus *et al*. 2006 \[[@CR30]\]6491414Donthineni *et al*. 2006 \[[@CR38]\]5175Kay *et al*. 1994 \[[@CR45]\]776\*3 of the 4 patients died of causes irrelevant to GCTB.Figure 1**A 22-year-old female patient came to the orthopedic clinic complaining of continuous pain of left knee, X-ray,CT, MRI and bone scan tests found a sub-articular lucent lesion with clear boundaries on the left distal femoral bone.**Figure 2**Pathological examination was fine needle biopsy confirmed it was giant cell tumor.** Local curettage and bone grafting was performed by the local hospital.Figure 3**18 months after the first surgery, CT and bone scan found local recurrence was found at follow-up visit.**Figure 4**She was treated with** ***en bloc*** **resection under the aid of computer navigation under intraoperative CT scan, and the cavity was filled with bone cement.** Intraoperative pathological exam confirmed the recurrence of GCTB.Figure 5**34 months after the first surgery, multiple nodules were found by CT scan in both of her lungs on a follow-up visit.**Figure 6**At the last follow-up visit 40 months after the first surgery, Ct scan showed that the patient was alive with the disease, complaining of no trouble with breathing.**

Conclusions {#Sec10}
===========

In conclusion, GCTB is normally considered a benign bone tumor. However, it may occasionally metastasize to vital organs such as the lung. The prognosis can be successful with timely and appropriate surgical treatment and chemotherapy. With the development of novel surgical methods and application of new drugs, most patients with GCTB can still achieve successful treatment results.
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